Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Sanofi Genzyme.

Community Practice Connections™: Stem Cell Mobilization 101: Maximizing Outcomes in Patients With Multiple Myeloma and Non-Hodgkin Lymphoma

Release Date: April 28, 2020
Expiration Date: April 28, 2021

Activity Overview

Autologous stem cell transplantation (ASCT) plays a key role in the treatment of hematologic malignancies, especially multiple myeloma and lymphoma. Mobilizing stem cells from the bone marrow for peripheral blood collection is an important procedure that circumvents the need for bone marrow harvest, which comes with additional complications. However, conventional stem cell mobilization techniques fail to mobilize an adequate number of stem cells for transplantation in up to 40% of patients. In this activity, expert faculty perspectives are integrated via video interviews into updates on the latest data for improving stem cell mobilization. Faculty will review the latest advances in improving stem cell mobilization outcomes. Strategies, techniques, and therapeutic options to optimize mobilization will be discussed and placed in the context of clinical scenarios to enhance your understanding of how new data should be applied to your patients. Additionally, ongoing clinical trials and new approaches to improve mobilization will be reviewed.

Acknowledgement of Support

This activity is supported by an educational grant from Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is intended for hematologists, medical oncologists, researchers, and investigators who treat or are interested in the treatment of patients with hematologic malignancies. Other allied healthcare professionals, including nurse practitioners, physician assistants, and nurses involved in the treatment and management of patients with hematologic malignancies, are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Review current strategies for stem cell mobilization in patients with multiple myeloma and non-Hodgkin lymphoma undergoing ASCT.
  • Utilize optimal strategies to individualize stem cell mobilization outcomes in the context of mitigating treatment-related toxicities.
  • Assess recent clinical trial evidence regarding agents available to increase the efficacy of stem cell mobilization.
  • Integrate recent data into current clinical practice to optimize personalized approaches for stem cell mobilization among patients with multiple myeloma and non-Hodgkin lymphoma

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Parameswaran Hari, MD, MRCP
Parameswaran Hari, MD, MRCP
Armand J. Quick/William F. Stapp Professor of Hematology
Chief, Division of Hematology and Oncology
Department of Medicine
Medical College of Wisconsin
Milwaukee, WI

Disclosures: Consulting Honoraria: Bristol Myers Squibb, Takeda, Amgen, Janssen, Karyopharm, Juno, GlaxoSmithKline, AbbVie.

Shaji Kumar, MD
Shaji Kumar, MD
Professor of Medicine
Department of Hematology
Consultant, Division of Hematology
Department of Internal Medicine
Mayo Clinic
Rochester, MN

Disclosures: Grant Research Support: Celgene, Takeda, Janssen, Bristol Myers Squibb, Sanofi, Kite Pharma, Merck, AbbVie, MedImmune, Novartis, Roche-Genentech, Amgen, Tenebrio, Carsgen; Consultant: (with no personal payments) Celgene, Takeda, Janssen, Kite Pharma, Merck, AbbVie, MedImmune, Genentech, Amgen, Molecular Partners and (with personal payment) Oncopeptides, Adaptive, Genecentrix.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By